デフォルト表紙
市場調査レポート
商品コード
1193005

固形腫瘍検査市場:タイプ別、用途別、エンドユーザー別:世界の機会分析、産業予測、2021-2031年

Solid Tumor Testing Market By Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 225 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.08円
固形腫瘍検査市場:タイプ別、用途別、エンドユーザー別:世界の機会分析、産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 225 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

固形腫瘍検査の世界市場は、2021年に237億5,140万米ドル、2031年には467億2,220万米ドルに達すると予測され、2022年から2031年までのCAGRは7.0%を記録しています。

固形腫瘍検査は、原発腫瘍を評価し、転移の範囲や場所を特定するために使用される手順です。腫瘍検査によって、がん細胞の拡散を回避するための効果的な治療法を検討することができます。腫瘍とは、異常な細胞の塊のことです。固形腫瘍の場合、腫瘍の中に液体や嚢胞がないことを意味します。固形腫瘍検査は、臨床診断において固形腫瘍の同定と可視化に使用される貴重な技術です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 固体腫瘍検査市場:タイプ別

  • 概要
    • 市場規模および予測
  • 遺伝子検査
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別分析
    • 遺伝子検査固形腫瘍検査市場: 遺伝子検査タイプ別
      • 次世代シーケンサー(NGS)市場規模・予測:地域別
      • リアルタイムPCR(RT-PCR)市場規模・予測:地域別
      • 蛍光in-situハイブリダイゼーション(FISH)市場規模・予測:地域別
      • フラグメント解析の市場規模・予測:地域別
  • 従来型検査
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第5章 固形腫瘍検査市場:用途別

  • 概要
    • 市場規模および予測
  • 前立腺
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 乳房
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 大腸
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 子宮内膜
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • メラノーマ
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 脳腫瘍
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 甲状腺
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 肝臓
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 卵巣
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第6章 固形腫瘍検査市場:エンドユーザー別

  • 概要
    • 市場規模・予測
  • 病院
    • 主な市場動向、成長要因と機会
    • 市場規模・予測: 地域別
    • 市場分析:国別
  • 製薬会社、バイオテクノロジー会社
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 受託研究機関
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 学術研究機関
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第7章 固形腫瘍検査市場:地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米の市場規模・予測:タイプ別
      • 北米の遺伝子検査固形腫瘍検査市場:遺伝子検査タイプ別
    • 北米の市場規模・予測:用途別
    • 北米市場規模・予測:エンドユーザー別
    • 北米市場規模・予測:国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測:タイプ別
      • 欧州遺伝子検査固形腫瘍検査市場:遺伝子検査タイプ別
    • 欧州市場規模・予測:用途別
    • 欧州市場規模・予測:エンドユーザー別
    • 欧州市場規模・予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他欧州
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測:タイプ別
      • アジア太平洋地域の遺伝子検査固形腫瘍検査市場:遺伝子検査タイプ別
    • アジア太平洋地域の市場規模・予測:用途別
    • アジア太平洋地域の市場規模・予測:エンドユーザー別
    • アジア太平洋地域の市場規模・予測:国別
      • 日本
      • 中国
      • オーストラリア
      • インド
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測:タイプ別
      • LAMEAの遺伝子検査固形腫瘍検査市場:遺伝子検査タイプ別
    • LAMEAの市場規模・予測:用途別
    • LAMEAの市場規模・予測:エンドユーザー別
    • LAMEAの市場規模・予測:国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • QIAGEN
  • QUEST DIAGNOSTICS INCORPORATED
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Biocare Medical LLC
  • , F. Hoffmann-La Roche AG
  • ILLUMINA, INC.
  • MedGenome Labs Private Ltd
  • MYRIAD GENETICS, INC.
  • Thermo Fisher Scientific, Inc.
図表

LIST OF TABLES

  • TABLE 1. GLOBAL SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 2. SOLID TUMOR TESTING MARKET, FOR GENETIC TESTING, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. SOLID TUMOR TESTING MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. GLOBAL GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
  • TABLE 5. SOLID TUMOR TESTING MARKET, FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2021-2031 ($MILLION)
  • TABLE 6. SOLID TUMOR TESTING MARKET, FOR REAL-TIME PCR (RT-PCR), BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. SOLID TUMOR TESTING MARKET, FOR FLUORESCENT IN-SITU HYBRIDIZATION (FISH), BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. SOLID TUMOR TESTING MARKET, FOR FRAGMENT ANALYSIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. SOLID TUMOR TESTING MARKET, FOR CONVENTIONAL TESTING, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. SOLID TUMOR TESTING MARKET FOR CONVENTIONAL TESTING, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 12. SOLID TUMOR TESTING MARKET, FOR PROSTATE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. SOLID TUMOR TESTING MARKET FOR PROSTATE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 14. SOLID TUMOR TESTING MARKET, FOR BREAST, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. SOLID TUMOR TESTING MARKET FOR BREAST, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. SOLID TUMOR TESTING MARKET, FOR COLORECTAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. SOLID TUMOR TESTING MARKET FOR COLORECTAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. SOLID TUMOR TESTING MARKET, FOR ENDOMETRIAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. SOLID TUMOR TESTING MARKET FOR ENDOMETRIAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. SOLID TUMOR TESTING MARKET, FOR LUNG, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. SOLID TUMOR TESTING MARKET FOR LUNG, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 22. SOLID TUMOR TESTING MARKET, FOR MELANOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. SOLID TUMOR TESTING MARKET FOR MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. SOLID TUMOR TESTING MARKET, FOR BRAIN, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. SOLID TUMOR TESTING MARKET FOR BRAIN, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. SOLID TUMOR TESTING MARKET, FOR THYROID, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. SOLID TUMOR TESTING MARKET FOR THYROID, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. SOLID TUMOR TESTING MARKET, FOR LIVER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 29. SOLID TUMOR TESTING MARKET FOR LIVER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. SOLID TUMOR TESTING MARKET, FOR OVARIAN, BY REGION, 2021-2031 ($MILLION)
  • TABLE 31. SOLID TUMOR TESTING MARKET FOR OVARIAN, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. SOLID TUMOR TESTING MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 33. SOLID TUMOR TESTING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 34. GLOBAL SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 35. SOLID TUMOR TESTING MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 36. SOLID TUMOR TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 37. SOLID TUMOR TESTING MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 38. SOLID TUMOR TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 39. SOLID TUMOR TESTING MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 40. SOLID TUMOR TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 41. SOLID TUMOR TESTING MARKET, FOR ACADEMIC RESEARCH INSTITUTIONS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 42. SOLID TUMOR TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTIONS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 43. SOLID TUMOR TESTING MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 44. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 45. NORTH AMERICA GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
  • TABLE 46. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 47. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 48. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 49. U.S. SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 50. U.S. SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 51. U.S. SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 52. CANADA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 53. CANADA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 54. CANADA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 55. MEXICO SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 56. MEXICO SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 57. MEXICO SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 58. EUROPE SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 59. EUROPE GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
  • TABLE 60. EUROPE SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 61. EUROPE SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 62. EUROPE SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 63. GERMANY SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. GERMANY SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 65. GERMANY SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 66. FRANCE SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 67. FRANCE SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 68. FRANCE SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 69. UK SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 70. UK SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 71. UK SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 72. ITALY SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 73. ITALY SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 74. ITALY SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 75. SPAIN SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 76. SPAIN SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 77. SPAIN SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 78. REST OF EUROPE SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 79. REST OF EUROPE SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 80. REST OF EUROPE SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 81. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 82. ASIA-PACIFIC GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
  • TABLE 83. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 84. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 85. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 86. JAPAN SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 87. JAPAN SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 88. JAPAN SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 89. CHINA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 90. CHINA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 91. CHINA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 92. AUSTRALIA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 93. AUSTRALIA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 94. AUSTRALIA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 95. INDIA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 96. INDIA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 97. INDIA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH KOREA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH KOREA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 100. SOUTH KOREA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 101. REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 102. REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 103. REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 104. LAMEA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 105. LAMEA GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
  • TABLE 106. LAMEA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 107. LAMEA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 108. LAMEA SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 109. BRAZIL SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 110. BRAZIL SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 111. BRAZIL SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 112. SAUDI ARABIA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 113. SAUDI ARABIA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 114. SAUDI ARABIA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 115. SOUTH AFRICA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 116. SOUTH AFRICA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 117. SOUTH AFRICA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 118. REST OF LAMEA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 119. REST OF LAMEA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 120. REST OF LAMEA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 121.QIAGEN: COMPANY SNAPSHOT
  • TABLE 122.QIAGEN: OPERATING SEGMENTS
  • TABLE 123.QIAGEN: PRODUCT PORTFOLIO
  • TABLE 124.QIAGEN: NET SALES,
  • TABLE 125.QIAGEN: KEY STRATERGIES
  • TABLE 126.QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT
  • TABLE 127.QUEST DIAGNOSTICS INCORPORATED: OPERATING SEGMENTS
  • TABLE 128.QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 129.QUEST DIAGNOSTICS INCORPORATED: NET SALES,
  • TABLE 130.QUEST DIAGNOSTICS INCORPORATED: KEY STRATERGIES
  • TABLE 131.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 132.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 133.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 134.ABBOTT LABORATORIES: NET SALES,
  • TABLE 135.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 136.AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 137.AGILENT TECHNOLOGIES INC.: OPERATING SEGMENTS
  • TABLE 138.AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 139.AGILENT TECHNOLOGIES INC.: NET SALES,
  • TABLE 140.AGILENT TECHNOLOGIES INC.: KEY STRATERGIES
  • TABLE 141.BIOCARE MEDICAL LLC: COMPANY SNAPSHOT
  • TABLE 142.BIOCARE MEDICAL LLC: OPERATING SEGMENTS
  • TABLE 143.BIOCARE MEDICAL LLC: PRODUCT PORTFOLIO
  • TABLE 144.BIOCARE MEDICAL LLC: NET SALES,
  • TABLE 145.BIOCARE MEDICAL LLC: KEY STRATERGIES
  • TABLE 146., F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 147., F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 148., F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 149., F. HOFFMANN-LA ROCHE AG: NET SALES,
  • TABLE 150., F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
  • TABLE 151.ILLUMINA, INC.: COMPANY SNAPSHOT
  • TABLE 152.ILLUMINA, INC.: OPERATING SEGMENTS
  • TABLE 153.ILLUMINA, INC.: PRODUCT PORTFOLIO
  • TABLE 154.ILLUMINA, INC.: NET SALES,
  • TABLE 155.ILLUMINA, INC.: KEY STRATERGIES
  • TABLE 156.MEDGENOME LABS PRIVATE LTD: COMPANY SNAPSHOT
  • TABLE 157.MEDGENOME LABS PRIVATE LTD: OPERATING SEGMENTS
  • TABLE 158.MEDGENOME LABS PRIVATE LTD: PRODUCT PORTFOLIO
  • TABLE 159.MEDGENOME LABS PRIVATE LTD: NET SALES,
  • TABLE 160.MEDGENOME LABS PRIVATE LTD: KEY STRATERGIES
  • TABLE 161.MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
  • TABLE 162.MYRIAD GENETICS, INC.: OPERATING SEGMENTS
  • TABLE 163.MYRIAD GENETICS, INC.: PRODUCT PORTFOLIO
  • TABLE 164.MYRIAD GENETICS, INC.: NET SALES,
  • TABLE 165.MYRIAD GENETICS, INC.: KEY STRATERGIES
  • TABLE 166.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 167.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 168.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 169.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
  • TABLE 170.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.SOLID TUMOR TESTING MARKET SEGMENTATION
  • FIGURE 2.SOLID TUMOR TESTING MARKET,2021-2031
  • FIGURE 3.SOLID TUMOR TESTING MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.SOLID TUMOR TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.SOLID TUMOR TESTING MARKET,BY TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CONVENTIONAL TESTING SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 15.SOLID TUMOR TESTING MARKET,BY APPLICATION,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PROSTATE SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF BREAST SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF COLORECTAL SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ENDOMETRIAL SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF LUNG SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF MELANOMA SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF BRAIN SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF THYROID SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF LIVER SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OVARIAN SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF OTHERS SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 27.SOLID TUMOR TESTING MARKET,BY END USER,2021(%)
  • FIGURE 28.COMPARATIVE SHARE ANALYSIS OF HOSPITALS SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 31.COMPARATIVE SHARE ANALYSIS OF ACADEMIC RESEARCH INSTITUTIONS SOLID TUMOR TESTING MARKET,2021-2031(%)
  • FIGURE 32.SOLID TUMOR TESTING MARKET BY REGION,2021
  • FIGURE 33.U.S. SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 34.CANADA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 35.MEXICO SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 36.GERMANY SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 37.FRANCE SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 38.UK SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 39.ITALY SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 40.SPAIN SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF EUROPE SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 42.JAPAN SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 43.CHINA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 44.AUSTRALIA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 45.INDIA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 46.SOUTH KOREA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 47.REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 48.BRAZIL SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 49.SAUDI ARABIA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 50.SOUTH AFRICA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 51.REST OF LAMEA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)
  • FIGURE 52. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 55.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 56.COMPETITIVE DASHBOARD
  • FIGURE 57.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 58.QIAGEN.: NET SALES ,($MILLION)
  • FIGURE 59.QUEST DIAGNOSTICS INCORPORATED.: NET SALES ,($MILLION)
  • FIGURE 60.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
  • FIGURE 61.AGILENT TECHNOLOGIES INC..: NET SALES ,($MILLION)
  • FIGURE 62.BIOCARE MEDICAL LLC.: NET SALES ,($MILLION)
  • FIGURE 63., F. HOFFMANN-LA ROCHE AG.: NET SALES ,($MILLION)
  • FIGURE 64.ILLUMINA, INC..: NET SALES ,($MILLION)
  • FIGURE 65.MEDGENOME LABS PRIVATE LTD.: NET SALES ,($MILLION)
  • FIGURE 66.MYRIAD GENETICS, INC..: NET SALES ,($MILLION)
  • FIGURE 67.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)
目次
Product Code: A04151

The global solid tumor testing market was valued at $ 23,751.4 million in 2021 and is projected to reach $ 46,722.2 million by 2031, registering a CAGR of 7.0% from 2022 to 2031. Solid tumor testing is a procedure used to evaluate the primary tumors and determine the extent/location of any metastases. The tumor testing in turn allows effective treatment options to be considered so that the spread of cancerous cells can be avoided. A tumor is an abnormal clump of cells. When someone has a solid tumor, that means the tumor doesn't contain any liquid or cysts. Solid tumor testing is a valuable technique that is used for the identification and visualization of solid tumors in clinical diagnostics.

In addition, Solid tumors can be tested through genetic testing and conventional testing. In genetic testing, there are various techniques such as next-generation sequencing (NGS), real-time PCR (RT-PCR), fluorescent In-Situ hybridization (FISH), and fragment analysis that are used for the diagnosis of tumors at early stages. In conventional testing, urine and blood tests, computerized tomography (CT) scan, bone scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, ultrasound and X-ray, and biopsy are used for the diagnosis of solid tumors.

The key factors that drive the growth of the market are an increase in the prevalence of the geriatric population that is prone to solid tumors, a rise in the prevalence of solid tumors in the world, and a rise in healthcare expenditure boosts the market growth.

For instance, according to American Cancer Society January 2021, estimated new cancer cases of Female breast (281,550), Uterine cervix (14,480), Colon & rectum (149,500), Uterine corpus (66,570), Lung & bronchus (235,760), Melanoma of the skin (106,110), non-Hodgkin lymphoma (81,560), Prostate (248,530), Urinary bladder (83,730) were diagnosed in 2021 in the U.S. Each year, approximately 4,00,000 children develop cancer. Overall cancer incidence rates, or rates of new cancers, continue to rise slightly in women and children

However, the dearth of skilled professionals restricts the market growth in the forecast period. Moreover, the rise in technological advancements in solid tumor testing, the increase in several type approvals, and the availability of reimbursements for solid tumor testing tests offer lucrative opportunities to the market players operating in the solid tumor testing market.

The global Solid tumor testing market is segmented into type, application, end-user, and region. By type, the market is categorized into genetic testing and conventional testing. The genetic testing segment is further classified into next-generation sequencing (NGS), real-time PCR (RT-PCR), fluorescent In-Situ hybridization (FISH), and fragment analysis. By application, the market is segmented into prostate, breast, colorectal, endometrial, lung, melanoma, brain, thyroid, liver, ovarian, and others (vaginal & vulvar, bladder, cervical, head & neck, and mesothelioma). By end user, the market is categorized into hospitals, pharmaceutical, and biotechnology companies, contract research organizations, and academic research institutions. By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global Solid tumor testing market are Abbott Laboratories, Agilent Technologies, Biocare Medical, LLC., F. Hoffmann-La Roche Ltd, Illumina, Inc., MedGenome, Myriad Genetics, QIAGEN N.V., Quest Diagnostics, and Thermo Fischer Scientific, Inc

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the solid tumor testing market analysis from 2021 to 2031 to identify the prevailing solid tumor testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the solid tumor testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes an analysis of the regional as well as global solid tumor testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Genetic Testing
    • Genetic Test Type
    • Next generation sequencing (NGS)
    • Real-time PCR (RT-PCR)
    • Fluorescent In-Situ Hybridization (FISH)
    • Fragment Analysis
  • Conventional Testing

By Application

  • Prostate
  • Breast
  • Colorectal
  • Endometrial
  • Lung
  • Melanoma
  • Brain
  • Thyroid
  • Liver
  • Ovarian
  • Others

By End User

  • Hospitals
  • Pharmaceutical and biotechnology companies
  • Contract research organizations
  • Academic research institutions

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • QIAGEN
    • QUEST DIAGNOSTICS INCORPORATED
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Biocare Medical LLC
    • , F. Hoffmann-La Roche AG
    • ILLUMINA, INC.
    • MedGenome Labs Private Ltd
    • MYRIAD GENETICS, INC.
    • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: SOLID TUMOR TESTING MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Genetic Testing
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Genetic Testing Solid Tumor Testing Market by Genetic Test Type
      • 4.2.4.1 Next generation sequencing (NGS) Market size and forecast, by region
      • 4.2.4.2 Real-time PCR (RT-PCR) Market size and forecast, by region
      • 4.2.4.3 Fluorescent In-Situ Hybridization (FISH) Market size and forecast, by region
      • 4.2.4.4 Fragment Analysis Market size and forecast, by region
  • 4.3 Conventional Testing
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: SOLID TUMOR TESTING MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Prostate
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Breast
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Colorectal
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Endometrial
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country
  • 5.6 Lung
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market analysis by country
  • 5.7 Melanoma
    • 5.7.1 Key market trends, growth factors and opportunities
    • 5.7.2 Market size and forecast, by region
    • 5.7.3 Market analysis by country
  • 5.8 Brain
    • 5.8.1 Key market trends, growth factors and opportunities
    • 5.8.2 Market size and forecast, by region
    • 5.8.3 Market analysis by country
  • 5.9 Thyroid
    • 5.9.1 Key market trends, growth factors and opportunities
    • 5.9.2 Market size and forecast, by region
    • 5.9.3 Market analysis by country
  • 6.0 Liver
    • 6.0.1 Key market trends, growth factors and opportunities
    • 6.0.2 Market size and forecast, by region
    • 6.0.3 Market analysis by country
  • 6.1 Ovarian
    • 6.1.1 Key market trends, growth factors and opportunities
    • 6.1.2 Market size and forecast, by region
    • 6.1.3 Market analysis by country
  • 6.2 Others
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country

CHAPTER 6: SOLID TUMOR TESTING MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Pharmaceutical and biotechnology companies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Contract research organizations
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country
  • 6.5 Academic research institutions
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market analysis by country

CHAPTER 7: SOLID TUMOR TESTING MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
      • 7.2.2.1 North America Genetic Testing Solid Tumor Testing Market by Genetic Test Type
    • 7.2.3 North America Market size and forecast, by Application
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Type
      • 7.2.5.1.2 Market size and forecast, by Application
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Type
      • 7.2.5.2.2 Market size and forecast, by Application
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Type
      • 7.2.5.3.2 Market size and forecast, by Application
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
      • 7.3.2.1 Europe Genetic Testing Solid Tumor Testing Market by Genetic Test Type
    • 7.3.3 Europe Market size and forecast, by Application
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Type
      • 7.3.5.1.2 Market size and forecast, by Application
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Type
      • 7.3.5.2.2 Market size and forecast, by Application
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Type
      • 7.3.5.3.2 Market size and forecast, by Application
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Type
      • 7.3.5.4.2 Market size and forecast, by Application
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Type
      • 7.3.5.5.2 Market size and forecast, by Application
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Type
      • 7.3.5.6.2 Market size and forecast, by Application
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
      • 7.4.2.1 Asia-Pacific Genetic Testing Solid Tumor Testing Market by Genetic Test Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Application
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Type
      • 7.4.5.1.2 Market size and forecast, by Application
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Type
      • 7.4.5.2.2 Market size and forecast, by Application
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Type
      • 7.4.5.3.2 Market size and forecast, by Application
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Type
      • 7.4.5.4.2 Market size and forecast, by Application
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Type
      • 7.4.5.5.2 Market size and forecast, by Application
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Type
      • 7.4.5.6.2 Market size and forecast, by Application
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
      • 7.5.2.1 LAMEA Genetic Testing Solid Tumor Testing Market by Genetic Test Type
    • 7.5.3 LAMEA Market size and forecast, by Application
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Type
      • 7.5.5.1.2 Market size and forecast, by Application
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Type
      • 7.5.5.2.2 Market size and forecast, by Application
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Type
      • 7.5.5.3.2 Market size and forecast, by Application
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Type
      • 7.5.5.4.2 Market size and forecast, by Application
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 QIAGEN
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 QUEST DIAGNOSTICS INCORPORATED
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Abbott Laboratories
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Agilent Technologies Inc.
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Biocare Medical LLC
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 , F. Hoffmann-La Roche AG
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 ILLUMINA, INC.
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 MedGenome Labs Private Ltd
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 MYRIAD GENETICS, INC.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Thermo Fisher Scientific, Inc.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments